RecruitingPhase 1NCT05469360

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Novartis Pharmaceuticals
Principal Investigator
Madhav Thambisetty, MD PhD
Novartis Pharmaceuticals
Intervention
NIO752(drug)
Enrollment
36 enrolled
Eligibility
30-74 years · All sexes
Timeline
2023 – 2028

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05469360 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials